|
WO2021065898A1
|
|
Azepan derivative
|
|
WO2021049628A1
|
|
P2x4 receptor antagonist
|
|
WO2021020547A1
|
|
Reagent cartridge
|
|
WO2021015108A1
|
|
Method for producing morphinan derivative
|
|
WO2021015109A1
|
|
Method for producing phenol derivative
|
|
WO2020246526A1
|
|
Enteric-coated preparation comprising xanthine oxidase inhibitor
|
|
WO2020246528A1
|
|
Therapeutic for gout or hyperuricemia
|
|
WO2020203610A1
|
|
Use of t-type calcium channel blocker for treating rheumatoid arthritis
|
|
JP2020164517A
|
|
Orally disintegrable tablet
|
|
WO2020203609A1
|
|
Use of t-type calcium channel blocker for treating pruritus
|
|
JP2020186221A
|
|
Method of stabilizing parkinson's disease therapeutic agent
|
|
JP2020105173A
|
|
Orally disintegrating tablet containing two or more drugs and method for producing the same
|
|
WO2020085234A1
|
|
Morphinan derivative
|
|
WO2020080398A1
|
|
Agent for suppressing alcohol sickness or hangover caused by alcoholic beverage intake
|
|
WO2020080394A1
|
|
Agent for improving quality of sleep
|
|
WO2020080399A1
|
|
Therapeutic or prophylactic agent for nocturia
|
|
CA3110619A1
|
|
Medicine for diabetic peripheral neuropathy
|
|
JP2020026431A
|
|
Orally disintegrating tablets
|
|
WO2020017569A1
|
|
T-type calcium channel blocker
|
|
JP2019142967A
|
|
Olmesartan prodrug formulation
|
